Biktarvy is Gilead Sciences' complete, single-tablet regimen for treating HIV-1, combining the integrase strand transfer inhibitor bictegravir with two nucleoside reverse transcriptase inhibitors, emtricitabine and tenofovir alafenamide. The FDA approved Biktarvy on February 7, 2018, and expanded its label in 2025 to cover treatment-experienced patients restarting antiretroviral therapy. It is taken once daily as a single tablet, requires no food restriction, and remains the top-selling HIV treatment in the United States.
Gilead set the 2026 wholesale acquisition cost for Biktarvy at $4,216 per 30-day supply, up from prior years. Almost no patient pays that list price directly. Commercially insured patients typically use the Gilead Advancing Access co-pay card to bring their cost to $0 to $5 per month, uninsured patients at or below 500% of the federal poverty level can receive Biktarvy free through the Gilead Advancing Access Patient Assistance Program, and Medicare Part D beneficiaries are protected by the 2026 annual out-of-pocket cap of $2,100. Medicaid, state AIDS Drug Assistance Programs (ADAP), and Ryan White HIV/AIDS Program clinics cover most of what remains for lower-income patients who fall through other cracks.
Biktarvy treats people already living with HIV; it is not FDA-approved for HIV prevention (PrEP). Patients researching HIV prevention drugs like Descovy or generic Truvada should instead look at how to get PrEP for free, including the federal Ready, Set, PrEP program, which covers PrEP medications for qualifying uninsured patients but does not apply to Biktarvy. Gilead does not expect a generic version of Biktarvy's three-drug combination on the US market before 2036 under current patent settlement agreements, so cost management for Biktarvy patients centers on manufacturer assistance, Medicare Part D rules, and ADAP rather than waiting for a generic.
What Biktarvy Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same biktarvy can cost many times more at a hospital than at your local pharmacy:
2026 Biktarvy Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash) | $3,800 - $5,280/month | 2026 cash price without insurance or assistance for a 30-day, 30-tablet supply |
| Medicare Part D (2026) | $0 - $460/month until the $2,100 annual cap is reached | Formulary tier and coverage phase determine your monthly share; Extra Help can reduce this further |
| Commercial insurance with Gilead co-pay card | $0 - $5/month, up to $7,200/year in savings | Prior authorization is common; card is for commercially insured patients only |
| Gilead Advancing Access PAP (uninsured) | $0/month | Free Biktarvy for uninsured patients at or below 500% FPL in 2026 |
| Medicaid / ADAP | $0 - $4/prescription | Most state Medicaid programs and all state AIDS Drug Assistance Programs (ADAP) cover Biktarvy |
Retail prices reflect 2026 pharmacy cash-price surveys (GoodRx, RxSaver, SingleCare). Part D and Medicaid ranges depend on your plan's formulary tier and state.
Source: CMS Part D 2026 benefit design, Gilead Advancing Access, HRSA Ryan White HIV/AIDS Program, GoodRx
Why Hospitals Charge So Much
Biktarvy is an outpatient, self-administered oral tablet, so it rarely appears on a hospital bill outside of an inpatient stay for an unrelated condition. When a hospital pharmacy dispenses a patient's home dose of Biktarvy during an admission, or supplies a bridge fill at discharge, the facility can bill the drug at several times its retail rate by adding pharmacy handling fees, medication reconciliation charges, and general facility overhead on top of the drug's acquisition cost.
If an itemized inpatient bill shows Biktarvy priced at $8,000 or more for a partial 30-day supply, ask the hospital billing office for the National Drug Code (NDC) and the per-tablet acquisition cost. The 2026 wholesale acquisition cost works out to roughly $140 per tablet. Charges well above that reflect facility markup, which Medicare and most commercial insurers will not fully reimburse, leaving the difference to be negotiated or appealed by the patient.
Patient Assistance Programs
Gilead Sciences runs the Gilead Advancing Access program, which combines insurance-status support, a commercial co-pay card, and a full Patient Assistance Program (PAP) that supplies free medication to eligible uninsured and underinsured patients. Compared to the $3,800 to $5,280 monthly retail cash price, Gilead Advancing Access can bring Biktarvy down to $0 for qualifying patients, making it one of the most generous manufacturer coupon and assistance combinations among branded specialty drugs.
Patient assistance programs for Biktarvy| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Gilead Advancing Access Co-pay Card | $0 - $5/month for commercially insured patients, up to $7,200/year in savings | gileadadvancingaccess.com |
| Gilead Advancing Access Patient Assistance Program (PAP) | Free Biktarvy for uninsured US patients at or below 500% of the federal poverty level | gileadadvancingaccess.com/patient |
| State AIDS Drug Assistance Program (ADAP) | Free or low-cost Biktarvy plus insurance premium and copay assistance; income limits vary by state | adap.directory |
| Ryan White HIV/AIDS Program | Comprehensive HIV care and medication support for low-income, uninsured, and underinsured patients | findhivcare.hrsa.gov |
If you have Medicare, Medicaid, TRICARE, or VA benefits, the Gilead Advancing Access co-pay card is blocked by the federal anti-kickback statute (42 U.S.C. Section 1320a-7b), which prohibits manufacturer coupons from being used with federal health programs. Medicare and Medicaid patients should instead use the Gilead Advancing Access PAP, state ADAP, or Ryan White clinics, none of which are barred by that statute because they use income-based eligibility rather than acting as a copay coupon.
Source: Gilead Advancing Access, HRSA Ryan White HIV/AIDS Program, NASTAD ADAP Directory
Medicare Part D
Medicare Part D covers Biktarvy on nearly every plan formulary because HIV antiretrovirals are one of six protected drug classes that Part D plans must cover with few exceptions. For 2026, your total annual out-of-pocket cost across all Part D drugs combined, including Biktarvy, is capped at $2,100. That cap comes from the Inflation Reduction Act and replaced the old catastrophic-phase coinsurance structure.
Low-income Medicare beneficiaries should apply for Extra Help (the Part D Low-Income Subsidy), which can reduce Biktarvy copays to as little as a few dollars per month regardless of the $2,100 cap. Dual-eligible beneficiaries who have both Medicare and Medicaid typically pay $0 to a small nominal copay for Biktarvy through the Extra Help program.
The Medicare Prescription Payment Plan, available since 2025, lets beneficiaries spread their Part D out-of-pocket costs evenly across the calendar year instead of paying a large sum in a single month. Patients who fill a full year of Biktarvy early in the year and would otherwise face a large upfront copay should ask their Part D plan to enroll them in this payment plan.
Common Biktarvy Billing Errors
If you got a bill for Biktarvy above $500/month with commercial insurance, or above $460/month on Medicare Part D, check for these issues before paying:
- Co-pay accumulator adjustment: some commercial plans do not count Gilead's co-pay card contribution toward your deductible or out-of-pocket maximum, so you can hit a large bill later in the year even though the card covered your pharmacy copay upfront.
- Prior authorization lapse at plan renewal: many Part D and commercial plans require an annual PA renewal for Biktarvy. If your prescriber's office does not resubmit it on time, you can be billed the full retail rate at the pharmacy counter.
- 340B or ADAP duplicate discount errors at safety-net clinics, which can cause a claim to be billed twice or rejected. Ask the clinic pharmacy to confirm which program (Ryan White 340B, ADAP, or your insurance) processed the fill.
- Charged the deductible-phase rate after you already crossed the $2,100 Part D annual out-of-pocket cap for the calendar year.
- Split-fill or 15-day supply limits imposed by some specialty pharmacies, which can double your monthly copay if your plan charges a copay per fill rather than per 30-day supply.
- Inpatient hospital charge for a Biktarvy dose marked up to several thousand dollars for a single tablet when the 2026 wholesale cost is about $140 per tablet.
Frequently Asked Questions
Is there a generic version of Biktarvy?
No. As of 2026, there is no FDA-approved generic version of Biktarvy's three-drug combination (bictegravir/emtricitabine/tenofovir alafenamide). Under 2025 patent settlement agreements between Gilead and generic manufacturers Lupin, Laurus, and Cipla, no generic version of the adult-dose tablet is expected before April 1, 2036. Biktarvy is a small-molecule combination drug, so it will eventually face generic competition rather than biosimilar competition.
How do I apply for the Gilead Advancing Access patient assistance program?
Visit gileadadvancingaccess.com or call 1-800-226-2056 to start. Your HIV provider's office typically submits the enrollment form on your behalf. You will need proof of household income, proof of US residency, and proof that you have no prescription drug coverage. Uninsured patients at or below 500 percent of the federal poverty level qualify for free Biktarvy shipped to their home or provider's office, renewable annually.
Can I use the Biktarvy co-pay card with Medicare?
No. Federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars manufacturer co-pay cards from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. The Gilead Advancing Access co-pay card is for commercially insured patients only. If you have Medicare, use the Gilead Advancing Access Patient Assistance Program, Extra Help, your state AIDS Drug Assistance Program (ADAP), or a Ryan White HIV/AIDS Program clinic instead.
What if my insurance denies coverage for Biktarvy?
Request the written denial reason, then file a formal appeal within 60 days with your prescriber's supporting clinical notes. HIV antiretrovirals are one of Medicare Part D's six protected drug classes, which limits how often plans can deny them outright. If the appeal fails, escalate to external review, and apply for the Gilead Advancing Access PAP, ADAP, or a Ryan White clinic in the meantime so your treatment is never interrupted.
Does the IRA negotiated Medicare price apply to Biktarvy?
No. Biktarvy was not selected for either the first round of Medicare drug price negotiation (prices effective January 1, 2026) or the second round (prices effective January 1, 2027, covering drugs like Ozempic and Trelegy Ellipta). Biktarvy remains subject to standard Medicare Part D rules, meaning your total annual out-of-pocket cost across all Part D drugs is capped at $2,100 in 2026 rather than a drug-specific Maximum Fair Price.
What does Biktarvy cost without insurance at the pharmacy counter in 2026?
Cash prices for a 30-day, 30-tablet supply of Biktarvy run about $3,800 to $5,280 in 2026, depending on the pharmacy. Walmart and Walgreens tend to price near $4,150 to $4,350, while Kroger and CVS with a free GoodRx or SingleCare coupon can bring the price closer to $4,100 to $4,200. Almost no eligible patient needs to pay this cash price because the Gilead Advancing Access PAP and ADAP cover most uninsured patients at no cost.
Do I qualify for the Gilead Advancing Access patient assistance program?
You likely qualify for the free PAP track if you are a US resident, have no prescription drug coverage, have a valid Biktarvy prescription from a licensed US provider, and your household income is at or below 500 percent of the federal poverty level, which is $79,800 for a single person or $165,000 for a household of four in 2026. If you have Medicare or Medicaid, you should apply for Extra Help, ADAP, or a Ryan White clinic rather than the commercial co-pay card.
Is Biktarvy the same as PrEP drugs like Descovy, and does Ready, Set, PrEP cover it?
No. Biktarvy treats people who already have HIV-1; it is not FDA-approved for HIV prevention (PrEP). Descovy and generic emtricitabine/tenofovir disoproxil fumarate (generic Truvada) are the FDA-approved PrEP options. The federal Ready, Set, PrEP program provides free PrEP medications to qualifying uninsured patients, but it does not cover Biktarvy since Biktarvy is a treatment drug, not a prevention drug. Patients seeking free PrEP should visit Ready, Set, PrEP directly rather than applying through Gilead Advancing Access for Biktarvy.
